These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15032571)

  • 41. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 42. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
    Druker BJ
    J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
    [No Abstract]   [Full Text] [Related]  

  • 43. Imatinib mesylate.
    Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
    [No Abstract]   [Full Text] [Related]  

  • 45. Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation.
    Eishei Oskuei A; Makhdoomi K; Abkhiz S; Vossoghian S; Farrokhpour M
    Arch Iran Med; 2014 May; 17(5):388-90. PubMed ID: 24784871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Part I: Milestones in personalised medicine--imatinib.
    Gambacorti-Passerini C
    Lancet Oncol; 2008 Jun; 9(6):600. PubMed ID: 18510992
    [No Abstract]   [Full Text] [Related]  

  • 47. STI571 revolution: can the newer targeted drugs measure up?
    Garber K
    J Natl Cancer Inst; 2001 Jul; 93(13):970-3. PubMed ID: 11438556
    [No Abstract]   [Full Text] [Related]  

  • 48. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
    Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
    Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is anticancer drug development heading in the right direction?
    Hambley TW; Hait WN
    Cancer Res; 2009 Feb; 69(4):1259-62. PubMed ID: 19208831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Attacking cancer at its root.
    Thompson CB
    Cell; 2009 Sep; 138(6):1051-4. PubMed ID: 19766556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.
    Chandra HS; Heisterkamp NC; Hungerford A; Morrissette JJ; Nowell PC; Rowley JD; Testa JR
    Cancer Genet; 2011 Apr; 204(4):171-9. PubMed ID: 21536234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Imatinib in treatment of thrombocythemia and other myeloproliferative diseases].
    Shu LL; Yang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1507-12. PubMed ID: 23257463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.
    Claiborn K
    J Clin Invest; 2011 Apr; 121(4):1227-8. PubMed ID: 21630503
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment for chronic myelogenous leukemia: the long road to imatinib.
    Hunter T
    J Clin Invest; 2007 Aug; 117(8):2036-43. PubMed ID: 17671637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis.
    Zimmermann J
    Future Med Chem; 2009 Nov; 1(8):1395-8. PubMed ID: 21426055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances of molecular targeted agents: opportunities for imaging.
    Dancey JE
    Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
    Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
    Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunological off-target effects of imatinib.
    Zitvogel L; Rusakiewicz S; Routy B; Ayyoub M; Kroemer G
    Nat Rev Clin Oncol; 2016 Jul; 13(7):431-46. PubMed ID: 27030078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The development history and future perspective of molecularly targeted therapy].
    Mizuki M; Kanakura Y
    Nihon Rinsho; 2014 Jun; 72(6):997-1003. PubMed ID: 25016795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted cancer therapies in the twenty-first century: lessons from imatinib.
    Stegmeier F; Warmuth M; Sellers WR; Dorsch M
    Clin Pharmacol Ther; 2010 May; 87(5):543-52. PubMed ID: 20237469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.